The CJC-1295 + Ipamorelin Blend combines the two most commonly paired GH secretagogues in endocrinology research, each acting through a distinct and complementary receptor pathway on anterior pituitary somatotroph cells. CJC-1295 without DAC (Mod GRF 1-29, 5mg) activates the GHRH receptor (GHRHR), a Gs-coupled GPCR that stimulates adenylyl cyclase → cAMP → PKA signaling to drive GH gene transcription and granule exocytosis. Ipamorelin (5mg) activates the ghrelin receptor (GHS-R1a), a Gq/11-coupled GPCR that signals through phospholipase C → IP3 → intracellular calcium mobilization.
The synergistic interaction between these two pathways is well-documented in published research. When both GHRHR and GHS-R1a are simultaneously activated, the cAMP and calcium signals converge within individual somatotroph cells to produce GH release that significantly exceeds the mathematical sum of each stimulus alone. This synergy is attributed to cross-potentiation at multiple levels: cAMP-dependent PKA phosphorylation enhances calcium channel conductance, while calcium/calmodulin-dependent kinases augment cAMP-responsive element binding. Additionally, Ipamorelin provides GH-selective stimulation without ACTH/cortisol elevation, ensuring clean experimental readouts.
Total content: 10mg per vial (5mg + 5mg). Co-lyophilized with ≥99% purity per component. Store at -20°C desiccated. For GH axis research only.
